Related Experiment Video
Updated: Sep 10, 2025
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Bioequivalence Study of Palbociclib Tablets in Healthy Volunteers
Yiting Hu1, Na Zhao1, Haojing Song1
1Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, People's Republic of China.
Objective:
Bioequivalence of palbociclib tablets was evaluated in healthy volunteers under fasting and fed conditions in this study.
Methods:
This bioequivalence trial, which randomized subjects to receive palbociclib under fed or fasted conditions, generated these results. High-performance liquid chromatography-mass spectrometry (HPLC-MS) was employed to determine palbociclib concentrations in plasma from collected blood samples. Pharmacokinetic (PK) parameters were calculated using the non-compartmental analysis (NCA) module within Phoenix WinNonlin version 8.2. Statistical analysis of key pharmacokinetic parameters-maximum plasma concentration (Cmax), area under the concentration-time curve from zero to last quantifiable time (AUC0-t), and area under the curve from zero to infinity (AUC0-∞)-was conducted using the bioequivalence (BE) module within WinNonLin. A total of 68 healthy subjects were enrolled and randomized to either a fasted or a fed group. All subjects were randomized into T-R and R-T sequences (T: test formulation; R: reference formulation).
Results:
The geometric mean ratios (T/R) of Cmax, AUC0-t and AUC0-∞ of palbociclib in plasma were 97.96%, 96.16%, and 96.02% under fasting conditions; The geometric mean ratios (T/R) of Cmax, AUC0-t and AUC0-∞ of palbociclib in plasma were 95.47%, 96.49%, and 96.36% under fed conditions. All 90% confidence intervals for the geometric mean ratios were contained entirely within the range of 80.00% to 125.00%. Under the fasted and fed conditions, the test preparation and the reference preparation of palbociclib tablets were bioequivalent. Adverse events (AEs) occurred at similar rates in the fasted and fed groups.
Conclusion:
The result indicated that the test preparation and the reference preparation of palbociclib tablets were bioequivalent under the fasted and fed conditions. The safety of the two preparations was good.
Clinical Trial Registration:
This trial was registered on the Chinese Clinical Trial website (http://www.chinadrugtrials.org.cn/index.html # CTR20220977).
More Related Videos
10:38Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Published on: December 16, 2022
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
01:16Bioequivalence: Overview
01:13Bioavailability: Overview
01:28Biopharmaceutics and Pharmacokinetics: Overview
01:16Methods for Studying Drug Absorption: In vitro
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...